Immune checkpoint receptor VISTA on immune cells is associated with expression of T-cell exhaustion marker TOX and worse prognosis in renal cell carcinoma with venous tumor thrombus
Authors:
Open Access
- 30 August 2022
- journal article
- research article
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 149 (7) , 4131-4139
Abstract
Purpose: The study aimed to determine the expression of VISTA and TOX within venous tumor thrombus and primary clear cell renal cell carcinoma (ccRCC) and to assess their prognostic value. Methods: The study enrolled 82 patients with ccRCC and coexisting venous tumor thrombus treated radically from 2012 to 2019 in two tertiary centers. Tissue microarrays were prepared and stained with respective antibodies. The expression of markers was assessed separately on tumor cells (TCs) and/or tumor-associated immune cells (TAICs). Results: TOX expression was positively correlated with the percentage of VISTA-positive TAICs in venous thrombus (p = 0.011), but not in the primary tumor (p = 0.674). High TOX expression was associated with a higher percentage of PD-L1-positive TAICs in both compartments (p = 0.001, p = 0.011, respectively). Positive expression of VISTA on TAICs was associated with PD-L1 expression on TCs (p = 0.005) and TAICs (p = 0.004) in the primary tumor, and only with PD-L1 on TAICs in thrombus (p = 0.006). The presence of VISTA-positive TAICs in venous thrombus was significantly more common in females (p = 0.034), and positively correlated with metastases (p = 0.028), and tumor necrosis (p = 0.013). The cases with VISTA-positive TAICs in venous tumor thrombi had significantly shorter OS than VISTA-negative cases (p = 0.041). Conclusion: For the first time, we demonstrated the expression of VISTA- and TOX-positive TAICs in the venous tumor thrombus. We found the association between immune checkpoint receptors and T cell exhaustion markers in both tumor mass and venous thrombus. Finally, we demonstrated that abundance of VISTA-positive TAICs in venous tumor thrombus correlates with worse outcomes in ccRCC.Keywords
Funding Information
- Gdański Uniwersytet Medyczny (01-0395/08/643)
This publication has 35 references indexed in Scilit:
- Baseline neutrophil to lymphocyte ratio combined with serum lactate dehydrogenase level associated with outcome of nivolumab immunotherapy in a Japanese advanced melanoma populationBritish Journal of Dermatology, 2018
- An Immune Atlas of Clear Cell Renal Cell CarcinomaCell, 2017
- Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancerLung Cancer, 2017
- Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signaturesGenome Biology, 2016
- Contralateral adrenal metastasis from renal cell carcinoma with tumor thrombus in the adrenal vein: a case reportJournal of Ultrasonography, 2015
- Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responsesProceedings of the National Academy of Sciences, 2015
- The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?Current Opinion in Immunology, 2015
- Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled TrialClinical Cancer Research, 2015
- CD40 expression in renal cell carcinoma is associated with tumor apoptosis, CD8+ T cell frequency and patient survivalHuman Immunology, 2014
- Kidney2010